Shares of Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC - Get Free Report) dropped 0.1% on Thursday . The stock traded as low as $10.44 and last traded at $10.44. Approximately 1,200 shares traded hands during trading, a decline of 97% from the average daily volume of 45,322 shares. The stock had previously closed at $10.45.
Oaktree Acquisition Corp. III Life Sciences Stock Performance
The firm's fifty day moving average price is $10.47.
Hedge Funds Weigh In On Oaktree Acquisition Corp. III Life Sciences
Institutional investors and hedge funds have recently bought and sold shares of the company. Shaolin Capital Management LLC acquired a new stake in shares of Oaktree Acquisition Corp. III Life Sciences during the 4th quarter worth approximately $5,478,000. AQR Arbitrage LLC purchased a new position in Oaktree Acquisition Corp. III Life Sciences in the fourth quarter worth approximately $19,743,000. K2 Principal Fund L.P. acquired a new stake in Oaktree Acquisition Corp. III Life Sciences during the fourth quarter worth $1,945,000. Lighthouse Investment Partners LLC purchased a new stake in Oaktree Acquisition Corp. III Life Sciences in the fourth quarter valued at $3,039,000. Finally, Sculptor Capital LP acquired a new position in shares of Oaktree Acquisition Corp. III Life Sciences in the 4th quarter valued at $2,490,000.
About Oaktree Acquisition Corp. III Life Sciences
(
Get Free Report)
Oaktree Acquisition Corp. III Life Sciences is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 1995 and is headquartered in Los Angeles, CA.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Oaktree Acquisition Corp. III Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oaktree Acquisition Corp. III Life Sciences wasn't on the list.
While Oaktree Acquisition Corp. III Life Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
